Key Highlights

  • GENinCode Plc (LSE:GENI) fell 7.41% on 7 October 2026, pushing the shares further into record low territory.
  • The predictive genetics company recently cut its 2026 Revenue forecast to approximately £3.2 million.
  • Lower-than-expected NHS sales and slower uptake through Thermo Fisher Scientific in the US and Europe drove the downgrade.
  • GENinCode said its cash runway extends into the first quarter of 2027, raising the prospect of a fundraise.
  • The shares fell about 21% on the day of the warning and have a 52-week range of roughly 0.64p to 4.90p.

GENinCode Share Price Falls on the FTSE AIM All-Share

Shares in GENinCode Plc (LSE:GENI), the UK-based predictive genetics company focused on the prevention of cardiovascular disease and ovarian cancer and a member of the FTSE AIM All-Share, dropped 7.41% on Wednesday, 7 October 2026. The move extended a heavy decline that began late last month when the company lowered its revenue expectations and highlighted a limited cash runway.

The shares fell about 21% to around 0.71p on the day of that update. They opened at about 0.65p on 1 October, close to a 52-week low of 0.64p, and Wednesday's drop pushed them to fresh lows. The company's Market Value now stands at only around £5 million, a fraction of its value at listing in 2021.

Why GENinCode Stock Moved Down

The primary reason is the revenue downgrade. GENinCode now expects revenue of approximately £3.2 million for 2026, below previous expectations. The company attributed the shortfall to lower-than-expected sales to the National Health Service and slower uptake of its tests through its distribution Partnership with Thermo Fisher Scientific in the US and Europe. For a growth company, a cut to the Top Line raises questions about the pace of adoption of its tests and the timeline to profitability.

The second reason is the cash runway. GENinCode said its existing resources would last into the first quarter of 2027. That leaves only a few months before the company must secure additional funding, and investors are concerned that any Equity raise at current prices would be highly dilutive. The prospect of a discounted placing often keeps buyers on the sidelines and encourages existing holders to sell.

The third reason is the latest interim figures, which showed a loss per share of 0.38p for the period. The company's net Margin remains deeply negative, and the Balance Sheet carries meaningful Debt relative to equity.

What GENinCode Does

GENinCode's in vitro diagnostic molecular tests combine clinical algorithms with genetic analysis to assess a patient's risk of developing disease. Its flagship focus is cardiovascular disease, where genetic risk scoring can help physicians identify patients who may benefit from earlier intervention. The company also has an ovarian cancer risk assessment programme. It operates in the UK, in Europe through GENinCode S.L.U. in Spain and in the US through GENinCode U.S. Inc.

The Thermo Fisher Partnership

GENinCode's distribution relationship with Thermo Fisher Scientific was expected to accelerate adoption of its tests in major markets. The recent update shows that uptake has been slower than hoped. Partnerships with large diagnostics groups can take time to ramp because of laboratory validation, reimbursement and clinician education. Investors will be watching for signs that sales through this channel are building.

NHS Adoption Challenges

The NHS remains an important market for GENinCode's cardiovascular tests. However, NHS procurement and funding cycles can be slow, and budget pressures across the health service have made it harder for new diagnostic products to win broad adoption. Lower NHS sales were a key Factor in the revenue downgrade.

Why Investors Are Watching LSE:GENI

Predictive and preventive medicine is a significant long-term opportunity, and cardiovascular disease remains one of the world's leading causes of death. GENinCode's technology addresses a genuine clinical need, and its partnership with a global diagnostics leader provides a route to market. The immediate challenge is financial: the company must secure funding while its share price is at record lows, and must show that revenue can grow fast enough to justify further investment.

What to Watch Next

  • Details of any fundraising or strategic financing before the first quarter of 2027.
  • Sales trends through the Thermo Fisher Scientific channel.
  • NHS adoption and reimbursement developments.
  • Progress on cost reduction to extend the cash runway.

Market Context

UK equities were subdued on 7 October 2026, with the FTSE 100 slipping after a flare-up in the Strait of Hormuz. Small healthcare companies with limited cash are particularly exposed when investors reduce risk.

Bottom Line

The 7.41% fall in GENinCode Plc (LSE:GENI) reflects the after-effects of a revenue forecast cut, a cash runway that extends only into early 2027 and worries over potential dilution. On the FTSE AIM All-Share, the company's next steps on funding and commercial traction through NHS and Thermo Fisher channels will determine whether the shares can recover from record lows.